Peptidic fusion inhibitors for SARS-CoV-2

Jan Münch[1], Elsa Sanchez-Garcia[2] and Frank Kirchhoff[1]

[1]Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany; [2]Computational Biochemistry, Center of Medical Biotechnology, University of Duisburg-Essen, 45117 Essen, Germany.
frank.kirchhoff@uni-ulm.de

Due to their safety, efficacy and specificity, peptide inhibitors hold great promise for the treatment of newly emerging viral pathogens. Here, I provide some examples for peptides inhibiting SARS-CoV-2 entry and outline the strategies used to design of peptides targeting the ACE2 receptor or the viral spike protein and its activating proteases furin, transmembrane serine protease 2 (TMPRSS2), or cathepsin L. In addition, I present examples for peptides that might exert broad activity against various members of the Coronavirus family.

[1] Schütz D, Ruiz-Blanco YB, Münch J, Kirchhoff F, Sanchez-Garcia E, Müller JA. (2020). Peptide and peptide-based inhibitors of SARS-CoV-2 entry. *Adv. Drug. Deliv. Rev*., **2020**, *167*, 47-65.

[2] Wettstein L, Conzelmann C, Müller JA, Weil T, Groß R, Hirschenberger M, Seidel A, Klute S, Zech F, Prelli Bozzo C, Preising N, Fois G, Lochbaum R, Knaff P, Mailänder V, Ständker L, Thal DR, Schumann C, Stenger S, Kleger A, Lochnit G, Sparrer K, Kirchhoff F, Frick M, Münch J. Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection. *Nat. Commun*. **2021**, *12*, 1726.

[3] Lu L, Xia S, Lan Q, Zhu Y, Wang C, Xu W, Li Y, Wang L, Jiao F, Zhou J, Hua C, Wang Q, Cai X, Wu Y, Gao J, Liu H, Sun G, Münch J, Kirchhoff F, Yuan Z, Xie Y, Sun F, Jiang J. Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. *Signal Transduction and Targeted Therapy* **2021**, *6*, 288.

[4] Wettstein L, Kirchhoff F, Münch J. The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment. *Int J Mol Sci*. **2022**, *23*, 1351.